Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 9/20 | 0.76 |
| ▸ | MEP1A | Q16819 | 2/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29417375 | 1.00 | MEP1B (0.76) | MEP1BMEP1AHDAC3HDAC1HDAC2 | |
| SCHEMBL19478235 | 0.92 | MEP1B (0.72) | MEP1BMEP1AHDAC3HDAC1HDAC2 | |
| SCHEMBL19510175 | 0.86 | MEP1B (1.00) | MEP1BMEP1ALMNA | |
| SCHEMBL19474704 | 0.83 | MEP1B (0.55) | MEP1BMEP1AHDAC3HDAC1HDAC2 | |
| SCHEMBL6510744 | 0.81 | MEP1B (0.56) | MEP1BMEP1ALMNARORCFFAR1 | |
| SCHEMBL19478284 | 0.78 | HDAC1 (0.79) | MEP1BHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28733027 | 0.77 | MEP1B (0.64) | MEP1BMEP1ALMNAFFAR1FFAR4 | |
| SCHEMBL28764949 | 0.76 | MEP1A (0.56) | MEP1BMEP1ARORC | |
| SCHEMBL19478276 | 0.76 | MEP1B (0.71) | MEP1BMEP1AHDAC3HDAC1HDAC2 | |
| SCHEMBL410067 | 0.75 | MEP1B (0.58) | MEP1BMEP1ALMNAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| CN-114507175-B | Novel inhibitors of hypnotins alpha and beta | 维沃里翁治疗股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-3967679-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Vivoryon Therapeutics AG (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3445744-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-10975019-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS AG (DE) | 2021-04-13 | — | — | US | disclosed |
| US-10975019-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS AG (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS N.V (DE) | 2019-05-02 | — | — | US | disclosed |
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS N.V (DE) | 2019-05-02 | — | — | US | disclosed |
| WO-2017182433-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017182433-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127317-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885HDAC3 2089/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885HDAC3 1850/4885 |
| US-10975019-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | MEP1B 2/4885MEP1A 1/4885HDAC3 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.